NCT01138007View on ClinicalTrials.gov

A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)

PHASE3CompletedINTERVENTIONAL
Enrollment

572

Participants

Timeline

Start Date

June 17, 2010

Primary Completion Date

August 1, 2012

Study Completion Date

August 7, 2012

Conditions
Depressive Disorder, Major
Interventions
DRUG

323U66 SR 150 mg tablet

323U66 SR 150 mg tablet is orally administered once in the morning and/or once in the evening during the teatment phase.

DRUG

323U66 SR 150 mg placebo tablet

323U66 SR 150 mg placebo tablet is orally administered once in the evening and/or once in the morning during the teatment phase.

Trial Locations (59)

470-1141

GSK Investigational Site, Aichi

479-0837

GSK Investigational Site, Aichi

802-0006

GSK Investigational Site, Fukuoka

810-0001

GSK Investigational Site, Fukuoka

810-0004

GSK Investigational Site, Fukuoka

810-0022

GSK Investigational Site, Fukuoka

812-0011

GSK Investigational Site, Fukuoka

815-0041

GSK Investigational Site, Fukuoka

960-0102

GSK Investigational Site, Fukushima

961-0021

GSK Investigational Site, Fukushima

963-0207

GSK Investigational Site, Fukushima

731-0121

GSK Investigational Site, Hiroshima

673-0891

GSK Investigational Site, Hyōgo

311-3193

GSK Investigational Site, Ibaraki

214-0014

GSK Investigational Site, Kanagawa

221-0835

GSK Investigational Site, Kanagawa

231-0023

GSK Investigational Site, Kanagawa

244-0816

GSK Investigational Site, Kanagawa

251-0055

GSK Investigational Site, Kanagawa

861-8002

GSK Investigational Site, Kumamoto

616-8421

GSK Investigational Site, Kyoto

639-0225

GSK Investigational Site, Nara

545-0001

GSK Investigational Site, Osaka

573-0032

GSK Investigational Site, Osaka

576-0054

GSK Investigational Site, Osaka

589-0011

GSK Investigational Site, Osaka

596-0076

GSK Investigational Site, Osaka

842-0192

GSK Investigational Site, Saga

843-0023

GSK Investigational Site, Saga

847-0053

GSK Investigational Site, Saga

341-0018

GSK Investigational Site, Saitama

420-0839

GSK Investigational Site, Shizuoka

321-0953

GSK Investigational Site, Tochigi

102-0071

GSK Investigational Site, Tokyo

110-0003

GSK Investigational Site, Tokyo

125-0041

GSK Investigational Site, Tokyo

141-0021

GSK Investigational Site, Tokyo

142-0051

GSK Investigational Site, Tokyo

150-0001

GSK Investigational Site, Tokyo

151-0053

GSK Investigational Site, Tokyo

154-0004

GSK Investigational Site, Tokyo

154-0012

GSK Investigational Site, Tokyo

160-0022

GSK Investigational Site, Tokyo

160-0023

GSK Investigational Site, Tokyo

164-0012

GSK Investigational Site, Tokyo

166-0011

GSK Investigational Site, Tokyo

170-0002

GSK Investigational Site, Tokyo

173-0004

GSK Investigational Site, Tokyo

180-0005

GSK Investigational Site, Tokyo

431-070

GSK Investigational Site, Gyeonggi-do

405-760

GSK Investigational Site, Incheon

110-746

GSK Investigational Site, Seoul

135-710

GSK Investigational Site, Seoul

136-705

GSK Investigational Site, Seoul

137-701

GSK Investigational Site, Seoul

138-736

GSK Investigational Site, Seoul

143-729

GSK Investigational Site, Seoul

150-713

GSK Investigational Site, Seoul

156-707

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01138007 - A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD) | Biotech Hunter | Biotech Hunter